Professor Fruchart is currently Professor in Pasteur Institute, President of R3i Foundation and a member of the International Atherosclerosis Society board.
Professor Fruchart has served as President of the Association for Research on Cholesterol, President of the Scientific Council of Lille University; President-Founder of Genfit; President of the International Atherosclerosis Society; President of the International Task Force for Prevention of Coronary Heart Disease.
Professor Fruchart has received many awards and honors: Member of the Academy of Medicine (1991); “Great Gold Medal of Pasteur Institute” (1994); Member of the Academy of Pharmacy (1995); “Chevalier de la Légion d’Honneur” (1995); Honoris Causa Doctor of the University of Buenos Aires (Argentina-1997) and of the University of Bucharest (Romania-2003); Visiting Professor of the University of Concepcion, (Chili-1997); “Officier des Palmes Académiques (1998); “Grand Prix Kuhlmann” (1998); “Galien” of Pharmaceutical Research (1998). “Gold Medal of Foundation Giovanni Lorenzini” award (2003); “Officier de la Légion d’Honneur” (2005); Anitschkow Prize (2008) and awarded for the “Memorial lecture of Arturo Fernandez-Cruz Foundation in Spain (2010).
He has published more than 900 original research papers in peer-reviewed journals. He discovered the molecular mechanism of action of fibrates through activation of PPAR-alpha and developed with Kowa the first SPPARMalpha K-877.
Professor Fruchart makes the following disclosures: Speakers’ Bureau for Solvay, Astra Zeneca UK, and sanofi-aventis. Professor Fruchart is a cofounder and President of the supervisory board of Genfit and serves as a consultant to Fournier Laboratories, Ltd., Astra Zeneca, Kowa Company, Ltd., and Pfizer Inc.